Characteristics of 574 patients with Staphylococcus aureus bacteremia (SAB), according to 12-week mortality
| Survivors | Non-survivors | P value | |
| 429 | 145 | ||
| Demographics | |||
| Age (y), median (IQR) | 68 (56–79) | 80 (72–86) | <0.001 |
| Sex, male n (%) | 169 (39) | 63 (43) | 0.434 |
| Comorbidities | |||
| Chronic lung disease, n (%) | 81 (61) | 52 (39) | <0.001 |
| Chronic heart failure, n (%) | 140 (33) | 92 (63) | <0.001 |
| Chronic renal insufficiency, n (%) | 127 (30) | 70 (48) | <0.001 |
| Chronic liver disease, n (%) | |||
| Diabetes mellitus, n (%) | 120 (28) | 39 (27) | 0.101 |
| Malignancy, n (%) | 131 (31) | 43 (30) | 0.917 |
| Immunodepression, n (%) | 160 (37) | 49 (34) | 0.485 |
| McCabe score, median (IQR) | 3 (3–3) | 3 (3–4) | <0.001 |
| Presumed place of acquisition | |||
| Nosocomial infection, n (%) | 213 (50) | 74 (51) | 0.848 |
| Presumed source of SAB | |||
| Skin, n (%) | 98 (23) | 21 (14) | 0.033 |
| Vascular, n (%) | 124 (29) | 25 (17) | 0.006 |
| Surgery, n (%) | 77 (18) | 21 (14) | 0.373 |
| Urinary tract, n (%) | 18 (4) | 5 (3) | 0.810 |
| Other, n (%) | 37 (9) | 14 (10) | 0.736 |
| Unidentified, n (%) | 74 (17) | 58 (40) | <0.001 |
| Clinical signs | |||
| Temperature ≤38°C, n (%) | 68 (16) | 36 (25) | 0.018 |
| Cardiac insufficiency, n (%) | 21 (5) | 25 (17) | <0.001 |
| Complicated bacteremia | |||
| Endocarditis (certain or probable), n (%) | 179 (42) | 68 (47) | 0.287 |
| Severe sepsis, n (%) | 53 (17) | 45 (46) | <0.001 |
| Septic shock, n (%) | 17 (6) | 35 (36) | <0.001 |
| Origin of infection | |||
| Osteoarticular, n (%) | 77 (18) | 14 (10) | 0.018 |
| Prosthetic infection, n (%) | 30 (7) | 4 (3) | 0.068 |
| Pneumonia, n (%) | 21 (5) | 21 (15) | <0.001 |
| Central nervous system, n (%) | 16 (4) | 15 (10) | 0.005 |
| Other complication, n (%) | 65 (15) | 29 (20) | 0.194 |
| Biological findings | |||
| C reactive protein (mg/dL), median (IQR) (421/139) | 199 (132–289) | 244 (162–342) | 0.008 |
| Procalcitonin (μg/L), median (IQR) (174/92) | 2.33 (0.78–13.2) | 8.11 (1.76–29.1) | <0.001 |
| Hemoglobin (g/L), median (IQR) (336/113) | 110 (96–123) | 105 (90–120) | 0.126 |
| Leukocytes (×109/L), median (IQR) (336/113) | 11.1 (7.7–16.0) | 13.5 (8.3–19.1) | 0.011 |
| Neutrophils (×109/L), median (IQR) (247/86) | 9.1 (5.7–13.7) | 11.6 (6.8–15.9) | 0.009 |
| Eosinophils (×109/L) (247/86) | 0 (0–100) | 0 (0–30) | 0.019 |
| Lymphocytes (×109/L), median (IQR) (247/86) | 750 (420–1180) | 690 (300–1030) | 0.132 |
| Monocytes (×109/L), median (IQR) (247/86) | 630 (370–970) | 590 (330–900) | 0.340 |
| Platelets (×109/L, median (IQR) (336/113) | 231 (154–317) | 205 (130–292) | 0.037 |
| Microbiological findings | |||
| Methicillin susceptibility, n (%) | 343 (80) | 106 (73) | 0.079 |
| Treatment | |||
| Intensive care unit admission, n (%) | 98 (23) | 52 (36) | 0.003 |
| Antibiotic therapy duration, median (IQR) | 22 (13–48) | 7 (3–14) | <0.001 |
| Mechanical ventilation, n (%) | 69 (26) | 32 (22) | 0.103 |
| Outcomes | |||
| Persistent severe sepsis at 48 h, n (%) | 41 (10) | 42 (29) | <0.001 |
| Persistent septic shock at 48 h, n (%) | 17 (4) | 37 (26) | <0.001 |